Resources

Client Alerts, News Articles, Blog Posts, & Multimedia

Everything you need to know about BMD and the industry.

Ohio Med Spas: Peptide Do's and Do Not's

Client Alert

Recent Ohio Board of Pharmacy (“BOP”) guidance has highlighted compliance considerations surrounding the use of peptides in med spas.  Owners and operators of med spas will want to keep these considerations in mind as the use of peptides, especially GLP-1 medications, expands.  

Certain peptide drugs are FDA approved medications and can be used in med spas. However, not every peptide-based drug is created equal or is approval by the FDA. According to BOP guidance, some peptides, such as Retatrutide, are not currently FDA approved.[1] In addition, many peptide-based drugs, such as Semaglutide or BPC-157 peptides, cannot currently be compounded.[2]

The BOP conducts regular inspections of med spas and has revoked or suspended several med-spa’s TDDD licenses for violations surrounding the use of peptides. The most common violations are purchasing medication from an unlicensed seller, purchasing and utilizing medication marked “for research purposes only,” purchasing non-FDA approved medication, and obtaining foreign sourced medication.   

When determining which peptides your med-spa can utilize, it is important to keep the following considerations in mind:

  • Only use peptides that are FDA approved.
  • Do not purchase peptides from unlicensed sellers.
  • Do not use peptides labeled “for research purposes only.”
  • Ensure compliance with compounding requirements, including not making prohibited copies of peptides.
  • Properly store any peptides prior to their use.

If you have questions regarding BOP compliance or how using peptides may impact your practice, please contact BMD Member Jeana Singleton at jmsingleton@bmdllc.com or 330-253-2001.     


[1] Compounding of Glucagon-like Peptide-1 Drug Products (GLP-1) in Ohio, Ohio Board of Pharmacy, last accessed April 23, 2026.

[1] Ten Common Prescriber Clinic and Medical Spa Violations, Ohio Board of Pharmacy, last accessed April 23, 2026. See also, Compounding of Glucagon-like Peptide-1 Drug Products (GLP-1) in Ohio, Ohio Board of Pharmacy, last accessed April 23, 2026.


New Construction Contract Requirement for Public Projects

Ohio Senate Bill 262, effective September 17, 2026, requires public authorities to mark modifications to industry-standard construction contracts using strikethrough and underline formatting. Unmarked changes are void, making compliance essential for public construction projects.

Understanding the Proposed H-1B Filing Fee Changes and the Impact on Workforce Planning

The Trump administration has proposed a substantial new fee for certain H-1B cap-subject petitions. Learn which employers and foreign national workers may be affected, what exemptions may apply, and key considerations for workforce planning.

What the $17 Billion Meta Settlement Means for Technology Companies

A historic $17.1 billion Meta settlement signals a new era of state attorney general enforcement, with important lessons for technology companies and digital platforms.

Update on Temporary Protected Status (TPS) for Haiti and Related Countries

USCIS has temporarily extended Employment Authorization Documents (EADs) for certain Temporary Protected Status (TPS) beneficiaries from Haiti and several other countries following recent court action. Employers and TPS recipients should review EAD expiration dates, monitor ongoing developments, and ensure compliance with Form I-9 and E-Verify requirements.

HHS Accessibility Requirements for Medical Diagnostic Equipment: What Health Care Providers Need to Know

Health care providers that receive federal financial assistance are now subject to updated HHS accessibility requirements for medical diagnostic equipment under Section 504 of the Rehabilitation Act. With the July 8, 2026, compliance deadline in effect, covered providers should ensure they have the required accessible equipment, train staff, and review operational practices to reduce compliance risk and provide accessible care for patients with disabilities.